Bevacizumab biosimilar is under clinical development by Prestige BioPharma and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bevacizumab biosimilar’s likelihood of approval (LoA) and phase transition for Peritoneal Cancer took place on 17 Nov 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bevacizumab biosimilar Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bevacizumab biosimilar overview

Bevacizumab biosimilar (HD-204) is under development for the treatment of metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic cervical cancer, recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer. The drug candidate is administered through intravenous route. It acts by targeting vascular endothelial growth factor A (VEGFA). It was also under development for the treatment of rectal cancer and metastatic renal cell carcinoma

Prestige BioPharma overview

Prestige BioPharma (PBP) is a biopharmaceutical company that discovers and develops biosimilars and antibody therapeutics for oncology and immune disorders. The company is investigating HD201, a trastuzumab biosimilar targeting breast cancer and gastric cancer; HD204, a bevacizumab biosimilar to treat solid tumors; PBP1502, adalimumab biosimilar against arthritis; and PBP1510 for the treatment of pancreatic cancer. It is evaluating biosimilars and antibody therapeutics in the areas of bone loss, osteoporosis, macular edema, metastatic colorectal cancer, retinopathy, metastatic and unresectable melanoma and others. PBP is also engaged in development of vaccine-based therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The company has operations in Australia, Belgium, South Korea and, the US. PBP is headquartered in Singapore City, Singapore.

Quick View Bevacizumab biosimilar LOA Data

Report Segments
  • Biosimilar
Drug Name
  • Bevacizumab biosimilar
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.